- Diclofenac Patches
- Lidocaine Patches
- Ketoprofen Patches
- Cpsaicin Patches
- Others
Non Opioid Pain Patch Market size was valued at USD 554.13 million in 2022 and is expected to reach USD 1279.02 million by 2029, at a CAGR of 12.68% from 2023-2029. Pain is a symptom, generally resulting from any infection, injury disease or disorder. Several people around the world suffer from different types of pains such as chronic pain, acute pain, lower back pain, neck pain, headache etc. Chronic pain usually last longer and intense. Pain is treated through the various treatments using, drugs, physical therapy and others. Nonopioid pain patches are kind of treatment for the pain. Opioid medicine is used by a huge number of people as a pain reliever. According to the United Nations Office on Drugs and Crime's figures, nearly 26.4 to 36 million persons worldwide abused opioids in 2012. There has been a rise in demand for non-opioid therapies due to an increase in the rate of addiction and severe side effects associated with long-term use of opioid medications. Non-opioid medicines have analgesic, antipyretic, and anti-inflammatory effects. These drugs work by blocking the enzyme cyclooxygenase at the site of injury, which then prevents the generation of prostaglandins, reducing the release of pain mediators in the peripheral nervous system. this report studies global Market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Non Opioid Pain Patch Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed global Non Opioid Pain Patch Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
With the rise in the number of people suffering from pain disorders, there is a greater demand for new ways to pain management. In addition, rising treatment expenses and an increase in the number of people suffering from chronic and acute pain are two important drivers driving market expansion. Furthermore, as people become more aware of the negative consequences of frequent opioid usage, demand for non-opioid medications has increased. Increased R&D to produce non-opioid medications in response to an increase in opioid medication addiction has fueled market expansion. However, negative concerns associated with long-term or excessive use of non-opioid medications, such as liver or kidney damage, may limit market expansion.
The non opioid pain patch market size was valued at USD 554.13 million in 2022
The non opioid pain patch market key players are: Omeros Camurus Orexo MediciNova Teva Pharmaceuticals Hikma Pharmaceuticals Reckitt Benckiser Pharmaceuticals, Inc. Mylan Dr. Reddy's Laboratories Addinex Technologies, Inc. Indivior Alkermes Titan Pharmaceuticals
The non opioid pain patch market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
1. Executive Summary |
2. Global Opioids Market Introduction |
2.1. Global Opioids Market Taxonomy |
2.2. Global Opioids Market Definitions |
2.2.1. By Drug Class |
2.2.2. By Distribution Channel |
2.2.3. By Treatment Centers |
2.2.4. By Route of Administration |
2.2.5. By Region |
3. Global Opioids Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Opioids Market Dynamic Factors - Impact Analysis |
3.6. Impact of COVID 19 on The Market |
3.7. Three Forecast Scenarios - Pessimistic, Conservative, and Opportunistic |
3.8. Mapping Market Players Activities |
3.9. Recent Key Developments |
3.10. Financial Status of the Market Players |
3.11. Recent Acquisitions, Collaborations, and Mergers |
4. Global Opioids Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Opioids Market Forecast, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
5.1. Naloxone |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Buprenorphine |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Methadone |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6. Global Opioids Market Forecast, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
6.1. Retail Pharmacies |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Hospitals |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Rehabilitation Centers |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Market Opportunity Analysis Global Opioids Market Forecast, By Treatment Centers, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
7.1. Residential Treatment Centers |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Outpatient Treatment Centers |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Inpatient Treatment Centers |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Market Opportunity Analysis Global Opioids Market Forecast, By Route of Administration, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
8.1. Oral |
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Parental |
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
9. Global Opioids Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia-Pacific |
9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Latin America |
9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Middle East and Africa |
9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
9.6. Global Opioids Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, Treatment Centers, Route of Administration, and Region, 2023 - 2029 |
10. North America Opioids Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
10.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
10.1.1. Naloxone |
10.1.2. Buprenorphine |
10.1.3. Methadone |
10.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
10.2.1. Retail Pharmacies |
10.2.2. Hospitals |
10.2.3. Rehabilitation |
10.3. Treatment Centers Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
10.3.1. Residential Treatment Centers |
10.3.2. Outpatient Treatment Centers |
10.3.3. Inpatient Treatment Centers |
10.4. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
10.4.1. Oral |
10.4.2. Parental |
10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
10.5.1. U.S. |
10.5.2. Canada |
10.6. North America Opioids Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, By Treatment Centers, Route of Administration, and Country, 2023 - 2029 |
10.7. North America Opioids Market Dynamics Trends |
11. Europe Opioids Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
11.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
11.1.1. Naloxone |
11.1.2. Buprenorphine |
11.1.3. Methadone |
11.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
11.2.1. Retail Pharmacies |
11.2.2. Hospitals |
11.2.3. Rehabilitation |
11.3. Treatment Centers Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
11.3.1. Residential Treatment Centers |
11.3.2. Outpatient Treatment Centers |
11.3.3. Inpatient Treatment Centers |
11.4. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
11.4.1. Oral |
11.4.2. Parental |
11.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
11.5.1. Germany |
11.5.2. UK |
11.5.3. France |
11.5.4. Italy |
11.5.5. Spain |
11.5.6. Rest of Europe |
11.6. Europe Opioids Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, By Treatment Centers, Route of Administration, and Country, 2023 - 2029 |
11.7. Europe Opioids Market Dynamics Trends |
12. Asia-Pacific Opioids Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
12.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
12.1.1. Naloxone |
12.1.2. Buprenorphine |
12.1.3. Methadone |
12.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
12.2.1. Retail Pharmacies |
12.2.2. Hospitals |
12.2.3. Rehabilitation |
12.3. Treatment Centers Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
12.3.1. Residential Treatment Centers |
12.3.2. Outpatient Treatment Centers |
12.3.3. Inpatient Treatment Centers |
12.4. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
12.4.1. Oral |
12.4.2. Parental |
12.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
12.5.1. Japan |
12.5.2. China |
12.5.3. India |
12.5.4. ASEAN |
12.5.5. Rest of Asia-Pacific |
12.6. Asia-Pacific Opioids Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, By Treatment Centers, Route of Administration, and Country, 2023 - 2029 |
12.7. Asia-Pacific Opioids Market Dynamics Trends |
13. Latin America Opioids Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
13.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
13.1.1. Naloxone |
13.1.2. Buprenorphine |
13.1.3. Methadone |
13.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
13.2.1. Retail Pharmacies |
13.2.2. Hospitals |
13.2.3. Rehabilitation |
13.3. Treatment Centers Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
13.3.1. Residential Treatment Centers |
13.3.2. Outpatient Treatment Centers |
13.3.3. Inpatient Treatment Centers |
13.4. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
13.4.1. Oral |
13.4.2. Parental |
13.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
13.5.1. Brazil |
13.5.2. Argentina |
13.5.3. Rest of Latin America |
13.6. Latin America Opioids Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, By Treatment Centers, Route of Administration, and Country, 2023 - 2029 |
13.7. Latin America Opioids Market Dynamics Trends |
14. Middle East and Africa Opioids Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
14.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
14.1.1. Naloxone |
14.1.2. Buprenorphine |
14.1.3. Methadone |
14.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
14.2.1. Retail Pharmacies |
14.2.2. Hospitals |
14.2.3. Rehabilitation |
14.3. Treatment Centers Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
14.3.1. Residential Treatment Centers |
14.3.2. Outpatient Treatment Centers |
14.3.3. Inpatient Treatment Centers |
14.4. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
14.4.1. Oral |
14.4.2. Parental |
14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
14.5.1. Saudi Arabia |
14.5.2. GCC Countries |
14.5.3. South Africa |
14.5.4. Rest of MEA |
14.6. MEA Opioids Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, By Treatment Centers, Route of Administration, and Country, 2023 - 2029 |
14.7. MEA Opioids Market Dynamics Trends |
15. Competition Landscape |
15.1. Strategic Dashboard of Top Market Players |
15.2. Company Profiles (Introduction, Financial Analysis, Drug Class Offerings, Key Developments, Strategies, and SWOT Analysis) |
15.2.1. Omeros |
15.2.2. Camurus |
15.2.3. Orexo |
15.2.4. MediciNova |
15.2.5. Teva Pharmaceuticals |
15.2.6. Â Hikma Pharmaceuticals |
15.2.7. Reckitt Benckiser Pharmaceuticals, Inc. |
15.2.8. Mylan |
15.2.9. Dr. Reddy's Laboratories |
15.2.10. Addinex Technologies, Inc. |
15.2.11. Indivior |
15.2.12. Alkermes |
15.2.13. Titan Pharmaceuticals |
16. Research Methodology |
17. Key Assumptions and Acronyms |